ABCG5

Across TCGA pan-cancer cohorts, ABCG5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ABCG5 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ABCG5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABCG5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, LUAD, and OV are the cancer types where ABCG5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.094	0.547	<.001	36	view →
LUAD	OS	Median	III,IV	0.197	0.673	<.001	24	view →
OV	DFS	Median	All	0.142	0.541	.002	12	view →
GBM	OS	Median	All	0.076	0.415	<.001	6	view →
UCEC	DFS	Median	All	0.923	0.618	.021	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ABCG5–LIHC (DFS)

Open the LIHC breakdown →